Inhibition of Aurora-B suppresses osteosarcoma cell migration and invasion

Experimental and Therapeutic Medicine

Volumn 7, Issue 3, 2014, Pages 560-564

  Zhu, Xiao Ping ^a   Liu, Zhi Li ^a   Peng, Ai Fen ^b   Zhou, Yun Fei ^a   Long, Xin Hua ^a   Luo, Qing Feng ^c   Huang, Shan Hu ^a   Shu, Yong ^a  

^a NANCHANG UNIVERSITY   (China)

^b JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c JIANGXI CANCER HOSPITAL   (China)

Author keywords

Aurora B; AZD1152; Metastasis; Osteosarcoma

Indexed keywords

EID: 84893021707     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1491     Document Type: Article

References (28)

1. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23: 2004-2011, 2005.
2. Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, et al: Local recurrence and local control of non-metastatic osteosarcoma of the extremities: A 27-year experience in a single institution. J Surg Oncol 96: 118-123, 2007.
3. Jawad MU, Cheung MC, Clarke J, Koniaris LG and Scully SP: Osteosarcoma: Improvement in survival limited to high-grade patients only. J Cancer Res Clin Oncol 137: 597-607, 2011.
4. Mialou V, Philip T, Kalifa C, Perol D, Gentet JC, Marec-Berard P, et al: Metastatic osteosarcoma at diagnosis: Prognostic factors and long-term outcome the French pediatric experience. Cancer 104: 1100-1109, 2005.
5. Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss J, Szendroi M, et al: Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy. Pediatr Blood Cancer 57: 415-422, 2011.
6. Zhang L and Zhang S: ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin. J Obstet Gynaecol Res 37: 591-600, 2011.
7. Wang WR, Yang SS, Lin JX, Zeng ZY, Liu DM and Liu HT: Expression of Aurora-B in non-small cell lung cancer and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao 29: 1853-1856, 2009 (In Chinese).
8. Qi G, Ogawa I, Kudo Y, Miyauchi M, Siriwardena BS, Shimamoto F, et al: Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch 450: 297-302, 2007.
9. Abdullah AS, Foong C and Murata-Hori M: Specific distribution of overexpressed Aurora-B kinase during interphase of normal epithelial cells. Cancer Cell Int 5: 31, 2005.
10. Li Y, Zhou W, Wei L, Jin J, Tang K, Li C, et al: The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma. Int J Oncol 41: 2139-2149, 2012.
11. Tuncel H, Shimamoto F, Kaneko Guangying Qi H, Aoki E, Jikihara H, et al: Nuclear Aurora-B and cytoplasmic Survivin expression is involved in lymph node metastasis of colorectal cancer. Oncol Lett 3: 1109-1114, 2012.
12. Pohl A, Azuma M, Zhang W, Yang D, Ning Y, Winder T, et al: Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer. Pharmacogenomics J 11: 93-99, 2011.
13. Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, et al: Antineoplastic effects of an Aurora-B kinase inhibitor in breast cancer. Mol Cancer 9: 42, 2010.
14. Chen YJ, Chen CM, Twu NF, Yen MS, Lai CR, Wu HH, et al: Overexpression of Aurora-B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch 455: 431-440, 2009.
15. Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, et al: The selective Aurora-B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 140: 295-302, 2008.
16. Adams RR, Eckley DM, Vagnarelli P, Wheatley SP, Gerloff DL, Mackay AM, et al: Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed in tumour cells. Chromosoma 10: 65-74, 2011.
17. Yoon MJ, Park SS, Kang YJ, Kim IY, Lee JA, Lee JS, et al: Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin. Carcinogenesis 33: 492-500, 2012.
18. Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MW, Calvert VS, Petricoin EF, et al: Aurora kinases in childhood acute leukemia: the promise of Aurora-B as therapeutic target. Leukemia 27: 560-568, 2013.
19. Xie F, Lang Q, Zhou M, Zhang H, Zhang Z, Zhang Y, et al: The dietary flavonoid luteolin inhibits Aurora-B kinase activity and blocks proliferation of cancer cells. Eur J Pharm Sci 46: 388-396, 2012.
20. Li J, Hu H, Lang Q, Zhang H, Huang Q, Wu Y and Yu L: A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora-B kinase activity. Eur J Med Chem 65: 151-157, 2013.
21. Yamauchi T, Uzui K, Shigemi H, Negoro E, Yoshida A and Ueda T: Aurora-B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells. Cancer Sci 104: 926-933, 2013.
22. Li J, Lang Q, Zhang H, Huang Q and Yu L: S39, a novel Aurora B kinase inhibitor, shows potent antineoplastic activity in human Hela cervical cancer cell line. Biotechnol Lett 35: 853-860, 2013.
23. Xie H, Lee MH, Zhu F, Reddy K, Peng C, Li Y, Lim do Y, et al: Identification of an Aurora kinase inhibitor specific for the Aurora-B isoform. Cancer Res 73: 716-724, 2013.
24. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, et al: AZD1152, a selective inhibitor of Aurora-B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13: 3682-3688, 2007.
25. Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, et al: AZD1152, a novel and selective Aurora-B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 110: 2034-2040, 2007.
26. Azzariti A, Bocci G, Porcelli L, Fioravanti A, Sini P, Simone GM, et al: Aurora-B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br J Cancer 104: 769-780, 2011.
27. Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP, et al: Aurora-B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J Biol Chem 287: 29887-29998, 2012.
28. Takeshita M, Koga T, Takayama K, Ijichi K, Yano T, Maehara Y, et al: Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer. Lung Cancer 80: 85-90, 2013.